Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP

Background COVID-19 restrictions led to increased reports of depressive symptoms in the general population and impacted health and social care services. We explored whether these changes affected antidepressant prescribing trends in the general population and those with learning disability or autism...

Full description

Saved in:
Bibliographic Details
Main Authors: Ben Goldacre, David Evans, Orla Macdonald, Richard Croker, Rebecca Smith, Christopher Wood, Andrea Schaffer, Andrew Brown, Brian MacKenna, William Hulme, Chris Bates, Amir Mehrkar, Peter Inglesby, John Parry, Amelia Green, Helen Curtis, Alex Walker, Rose Higgins, Sebastian Bacon, Simon Davy, Tom Ward, Louis Fisher, Iain Dillingham, Milan Wiedemann, Lucy Bridges, Ben Butler-Cole, Colm Andrews, Christine Cunningham, Victoria Speed, Liam C Hart, Thomas O’Dwyer, Steve Maude
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:BMJ Mental Health
Online Access:https://mentalhealth.bmj.com/content/28/1/e301378.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849313795116105728
author Ben Goldacre
David Evans
Orla Macdonald
Richard Croker
Rebecca Smith
Christopher Wood
Andrea Schaffer
Andrew Brown
Brian MacKenna
William Hulme
Chris Bates
Amir Mehrkar
Peter Inglesby
John Parry
Amelia Green
Helen Curtis
Alex Walker
Rose Higgins
Sebastian Bacon
Simon Davy
Tom Ward
Louis Fisher
Iain Dillingham
Milan Wiedemann
Lucy Bridges
Ben Butler-Cole
Colm Andrews
Christine Cunningham
Victoria Speed
Liam C Hart
Thomas O’Dwyer
Steve Maude
author_facet Ben Goldacre
David Evans
Orla Macdonald
Richard Croker
Rebecca Smith
Christopher Wood
Andrea Schaffer
Andrew Brown
Brian MacKenna
William Hulme
Chris Bates
Amir Mehrkar
Peter Inglesby
John Parry
Amelia Green
Helen Curtis
Alex Walker
Rose Higgins
Sebastian Bacon
Simon Davy
Tom Ward
Louis Fisher
Iain Dillingham
Milan Wiedemann
Lucy Bridges
Ben Butler-Cole
Colm Andrews
Christine Cunningham
Victoria Speed
Liam C Hart
Thomas O’Dwyer
Steve Maude
author_sort Ben Goldacre
collection DOAJ
description Background COVID-19 restrictions led to increased reports of depressive symptoms in the general population and impacted health and social care services. We explored whether these changes affected antidepressant prescribing trends in the general population and those with learning disability or autism.Methods With the approval of NHS England, we used >24 million patients’ primary care data from the OpenSAFELY-TPP platform. We used interrupted time series analysis to quantify trends in those prescribed and newly prescribed an antidepressant across key demographic and clinical subgroups, comparing pre-COVID-19 (January 2018–February 2020), COVID-19 restrictions (March 2020–February 2021) and recovery (March 2021–December 2022) periods.Results Prior to COVID-19 restrictions, antidepressant prescribing was increasing in the general population and in those with learning disability or autism. We did not find evidence that the pandemic was associated with a change in antidepressant prescribing trend in the general population (relative risk (RR) 1.00 (95% CI 0.97 to 1.02)), in those with autism (RR 0.99 (95% CI 0.97 to 1.01)) or in those with learning disability (RR 0.98 (95% CI 0.96 to 1.00)).New prescribing post restrictions was 13% and 12% below expected had COVID-19 not happened in both the general population and those with autism (RR 0.87 (95% CI 0.83 to 0.93), RR 0.88 (95% CI 0.83 to 0.92)), but not learning disability (RR 0.96 (95% CI 0.87 to 1.05)).Conclusions and implications In this England study, we did not see an impact of COVID-19 on overall antidepressant prescribing, although unique trends were noted, such as trends in new antidepressant prescriptions which increased in care homes over the pandemic and decreased in the general population and those with autism since recovery.
format Article
id doaj-art-3f05e59bacb34d0cb6411c919c04077d
institution Kabale University
issn 2755-9734
language English
publishDate 2025-04-01
publisher BMJ Publishing Group
record_format Article
series BMJ Mental Health
spelling doaj-art-3f05e59bacb34d0cb6411c919c04077d2025-08-20T03:52:39ZengBMJ Publishing GroupBMJ Mental Health2755-97342025-04-0128110.1136/bmjment-2024-301378Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPPBen Goldacre0David Evans1Orla Macdonald2Richard Croker3Rebecca Smith4Christopher Wood5Andrea Schaffer6Andrew Brown7Brian MacKenna8William Hulme9Chris Bates10Amir Mehrkar11Peter Inglesby12John Parry13Amelia Green14Helen Curtis15Alex Walker16Rose Higgins17Sebastian Bacon18Simon Davy19Tom Ward20Louis Fisher21Iain Dillingham22Milan Wiedemann23Lucy Bridges24Ben Butler-Cole25Colm Andrews26Christine Cunningham27Victoria Speed28Liam C Hart29Thomas O’Dwyer30Steve Maude3111 Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKSchool of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, UKOxford Health NHS Foundation Trust, Oxford, UKBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK1Exeter IBD Pharmacogenetics Research Group, Exeter, UK2 University of Oxford, Oxford, UK1 Centre for Big Data Research in Health, UNSW Sydney, Sydney, New South Wales, AustraliaMedical University of South Carolina, Charleston, South Carolina, USA4 NHS England, Redditch, UKUniversity of Oxford, Oxford, UKTPP, Leeds, UK11 Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKTPP, Leeds, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK2 University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK11 Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK2 Nuffield Department of Primary Care, Oxford University, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK2 King`s Thrombosis Centre, Department of Haematological Medicine, King`s College Hospital NHS Foundation Trust, London, UKBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, The Bennett Institute for Applied Data Science, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, The Bennett Institute for Applied Data Science, University of Oxford, Oxford, UKBackground COVID-19 restrictions led to increased reports of depressive symptoms in the general population and impacted health and social care services. We explored whether these changes affected antidepressant prescribing trends in the general population and those with learning disability or autism.Methods With the approval of NHS England, we used >24 million patients’ primary care data from the OpenSAFELY-TPP platform. We used interrupted time series analysis to quantify trends in those prescribed and newly prescribed an antidepressant across key demographic and clinical subgroups, comparing pre-COVID-19 (January 2018–February 2020), COVID-19 restrictions (March 2020–February 2021) and recovery (March 2021–December 2022) periods.Results Prior to COVID-19 restrictions, antidepressant prescribing was increasing in the general population and in those with learning disability or autism. We did not find evidence that the pandemic was associated with a change in antidepressant prescribing trend in the general population (relative risk (RR) 1.00 (95% CI 0.97 to 1.02)), in those with autism (RR 0.99 (95% CI 0.97 to 1.01)) or in those with learning disability (RR 0.98 (95% CI 0.96 to 1.00)).New prescribing post restrictions was 13% and 12% below expected had COVID-19 not happened in both the general population and those with autism (RR 0.87 (95% CI 0.83 to 0.93), RR 0.88 (95% CI 0.83 to 0.92)), but not learning disability (RR 0.96 (95% CI 0.87 to 1.05)).Conclusions and implications In this England study, we did not see an impact of COVID-19 on overall antidepressant prescribing, although unique trends were noted, such as trends in new antidepressant prescriptions which increased in care homes over the pandemic and decreased in the general population and those with autism since recovery.https://mentalhealth.bmj.com/content/28/1/e301378.full
spellingShingle Ben Goldacre
David Evans
Orla Macdonald
Richard Croker
Rebecca Smith
Christopher Wood
Andrea Schaffer
Andrew Brown
Brian MacKenna
William Hulme
Chris Bates
Amir Mehrkar
Peter Inglesby
John Parry
Amelia Green
Helen Curtis
Alex Walker
Rose Higgins
Sebastian Bacon
Simon Davy
Tom Ward
Louis Fisher
Iain Dillingham
Milan Wiedemann
Lucy Bridges
Ben Butler-Cole
Colm Andrews
Christine Cunningham
Victoria Speed
Liam C Hart
Thomas O’Dwyer
Steve Maude
Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
BMJ Mental Health
title Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
title_full Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
title_fullStr Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
title_full_unstemmed Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
title_short Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
title_sort impact of the covid 19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism an interrupted time series analysis in england using opensafely tpp
url https://mentalhealth.bmj.com/content/28/1/e301378.full
work_keys_str_mv AT bengoldacre impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT davidevans impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT orlamacdonald impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT richardcroker impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT rebeccasmith impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT christopherwood impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT andreaschaffer impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT andrewbrown impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT brianmackenna impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT williamhulme impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT chrisbates impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT amirmehrkar impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT peteringlesby impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT johnparry impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT ameliagreen impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT helencurtis impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT alexwalker impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT rosehiggins impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT sebastianbacon impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT simondavy impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT tomward impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT louisfisher impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT iaindillingham impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT milanwiedemann impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT lucybridges impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT benbutlercole impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT colmandrews impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT christinecunningham impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT victoriaspeed impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT liamchart impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT thomasodwyer impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp
AT stevemaude impactofthecovid19pandemiconantidepressantprescribingwithafocusonpeoplewithlearningdisabilityandautismaninterruptedtimeseriesanalysisinenglandusingopensafelytpp